S. mussotii appears to be effective for treating liver diseases, such as jaundice, and we propose that S. mussotii can be used to treat NAFLD rats under conditions of hyperlipidaemia by regulating the TLR4/MyD88/NF-κB pathway. Here, MYD88 is linked to metabolic dysfunction-associated steatotic liver disease.